I7276
Anti-Insulin-Like Growth Factor-II antibody produced in goat
affinity isolated antibody, lyophilized powder
Synonyme(s) :
Anti-IGF-II
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Produits recommandés
Source biologique
goat
Niveau de qualité
Conjugué
unconjugated
Forme d'anticorps
affinity isolated antibody
Type de produit anticorps
primary antibodies
Clone
polyclonal
Forme
lyophilized powder
Espèces réactives
human
Technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 5-15 μg/mL using human Placenta
neutralization: 0.2-0.8 μg/mL
western blot: suitable
Numéro d'accès UniProt
Température de stockage
−20°C
Modification post-traductionnelle de la cible
unmodified
Informations sur le gène
human ... IGF2(3481)
Description générale
Insulin-like growth factors -I and -II are important regulators of signalling that mediates growth and metabolism in cells. Insulin-like growth factor -II (IGF-II) is widely expressed during embryonic stages and regulates the placental development. IGF-II acts via specific receptor, IGF-IIR, the binding does not result in signal transduction, but is a mechanism to restrict the bioavailability of IGF-II. IGF-II also binds to IGF-IR which results in the activation of MAPK, Raf/Ras and PI3K cascades. The effects of IGF-II signalling are important in growth of blood vessels (angiogenesis) gene transcription, proliferation and transformation. Irregular IGF-II signaling has been implicated in many cancers including lung cancer, colo-rectal cancer, cervical cancer, testicular cancer, rhabdosarcoma, melanoma and hepatoblastoma
Anti-IGF-II recognizes human insulin-like growth factor II. It does not react with human IGF-I.
Anti-IGF-II recognizes human insulin-like growth factor II. It does not react with human IGF-I.
Spécificité
The antibody will neutralize the biological activity of recombinant human IGF-II. It does not neutralize the biological activity of recombinant human IGF-I.
Immunogène
recombinant human IGF-II
Application
Anti- IGF-II antibody may be used for neutralization reactions, the ND50 of the antibody is 0.2-0.8 μg/ml. This antibody was used to neutralize IGF-II in glioblastoma cell lines. For immunohistochemistry a working antibody concentration of 5-15 μg/ml may be used for formalin-fixed, paraffin-embedded human placenta sections. The antibody is suitable for immunoblotting.
Forme physique
Lyophilized from a 0.2 μm filtered solution of phosphate buffered saline, pH 7.4, with 5% trehalose
Clause de non-responsabilité
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Produit(s) apparenté(s)
Réf. du produit
Description
Tarif
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 1
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Équipement de protection individuelle
Eyeshields, Gloves, type N95 (US)
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Antonino Belfiore et al.
Endocrine reviews, 30(6), 586-623 (2009-09-16)
In mammals, the insulin receptor (IR) gene has acquired an additional exon, exon 11. This exon may be skipped in a developmental and tissue-specific manner. The IR, therefore, occurs in two isoforms (exon 11 minus IR-A and exon 11 plus
Ramaswamy Suvasini et al.
The Journal of biological chemistry, 286(29), 25882-25890 (2011-05-27)
Glioblastoma is the most common and malignant form of primary astrocytoma. Upon investigation of the insulin-like growth factor (IGF) pathway, we found the IGF2BP3/IMP3 transcript and protein to be up-regulated in GBMs but not in lower grade astrocytomas (p <
Robert G Maki
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(33), 4985-4995 (2010-10-27)
Insulin-like growth factors were discovered more than 50 years ago as mediators of growth hormone that effect growth and differentiation of bone and skeletal muscle. Interest of the role of insulin-like growth factors in cancer reached a peak in the
Wendy Chao et al.
Cytokine & growth factor reviews, 19(2), 111-120 (2008-03-01)
Insulin-like growth factor II (IGF2) is perhaps the most intricately regulated of all growth factors characterized to date. Its gene is imprinted--only one allele is active, depending on parental origin--and this pattern of expression is maintained epigenetically in almost all
O Manousos et al.
International journal of cancer, 83(1), 15-17 (1999-08-17)
Recent data suggest that the IGF system plays an important role in the pathogenesis of several forms of human cancer, and there is evidence that IGFs acting in an autocrine and paracrine manner may also affect colorectal cancer risk. We
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique